Longitudinal changes of biochemical markers and bone

Objective : The aim of the present study was to clarify whether patients with Graves’ disease who have lost bone mass can restore bone mass to agematched control levels by antithyroid drug therapy. Patient/Materials and Methods : One male and 16 female patients (aged 21-71 years, mean±SE 39.9± 16.5) with untreated Graves’ disease were included in the study . Methimazole or propylthiouracil was given to all of the patients. Biochemical markers (serum N-mid osteocalcin (OCN-mid), alkaline phosphatase (ALP), type I collagen C-terminal telopeptide (sCTx), urinary pyridinoline (Pyr), deoxypyridinoline (Dpyr) and type I collagen C-terminal telopeptide (uCTx) and bone mineral density at the distal one third of the radius were assessed prior to treatment, and in the first, third, sixth and twelfth months of treatment. Results : All biochemical markers had increased significantly 12 months after treatment compared with the baseline values (OCN-mid, p<0.05 ; ALP, p< 0.01 ; sCTx, p<0.05 ; Pyr, Dpyr, uCTx, p<0.01). Among the biochemical markers, urinary Pyr and Dpyr had decreased the most prominently 12 months after treatment. However, BMD at the distal one third of the radius did not improve after 12 months of treatment. Conclusion : Based on assessments of BMD at the distal one third of the radius, one year is not enough to restore bone mass using antithyroid drug therapy in patients with Graves’ disease.

[1]  Masaaki Takahashi,et al.  Investigation of the performance of ELISA for N-terminal midfragment of osteocalcin , 1997, Journal of Bone and Mineral Metabolism.

[2]  F. Azizi,et al.  Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. , 2005, European journal of endocrinology.

[3]  A. Berghold,et al.  Variable bone mass recovery in hyperthyroid bone disease after radioiodine therapy in postmenopausal patients. , 2000, Maturitas.

[4]  H. Pantazi,et al.  Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. , 2000, The Journal of clinical endocrinology and metabolism.

[5]  R. Rovelli,et al.  Longitudinal Changes of Bone Density and Bone Resorption in Hyperthyroid Girls During Treatment , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  Masaaki Takahashi,et al.  Bone turnover and cortical bone mineral density in the distal radius in patients with hyperthyroidism being treated with antithyroid drugs for various periods of time , 1999, Clinical endocrinology.

[7]  J. Burrin,et al.  Tri-iodothyronine regulates the production of interleukin-6 and interleukin-8 in human bone marrow stromal and osteoblast-like cells. , 1998, The Journal of endocrinology.

[8]  Faber,et al.  Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women , 1998, Clinical endocrinology.

[9]  H. Sugimoto,et al.  Antithyroid therapy improves bony manifestations and bone metabolic markers in patients with Graves' thyrotoxicosis , 1997, Clinical endocrinology.

[10]  C. Christiansen,et al.  Measurement of Bone Degradation Products in Serum Using Antibodies Reactive with an Isomerized Form of an 8 Amino Acid Sequence of the C‐Telopeptide of Type I Collagen , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  C. Price,et al.  A longitudinal study of markers of bone turnover in Graves' disease and their value in predicting bone mineral density. , 1997, The Journal of clinical endocrinology and metabolism.

[12]  L. Braverman,et al.  Site selectivity of osteoblast gene expression response to thyroid hormone localized by in situ hybridization. , 1997, The American journal of physiology.

[13]  M. Miyakawa,et al.  Carboxy-terminal propeptide of type 1 procollagen (P1CP) and carboxy-terminal telopeptide of type 1 collagen (1CTP) as sensitive markers of bone metabolism in thyroid disease. , 1996, Endocrine journal.

[14]  C. Nappi,et al.  Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole. , 1996, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[15]  C. Christiansen,et al.  Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. , 1995, Clinical chemistry.

[16]  C. Christiansen,et al.  Immunoassay for quantifying type I collagen degradation products in urine evaluated. , 1994, Clinical chemistry.

[17]  P. Delmas,et al.  Markers of bone turnover in hyperthyroidism and the effects of treatment. , 1994, The Journal of clinical endocrinology and metabolism.

[18]  C. Marcocci,et al.  Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. , 1994, The Journal of clinical endocrinology and metabolism.

[19]  J. Britto,et al.  Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. , 1994, Endocrinology.

[20]  T. Ohishi,et al.  Urinary bone resorption markers in patients with metabolic bone disorders. , 1994, Bone.

[21]  T. Ohishi,et al.  Age-related changes of urinary pyridinoline and deoxypyridinoline in Japanese subjects. , 1993, Clinical and investigative medicine. Medecine clinique et experimentale.

[22]  K. Burman,et al.  Prevalence of fractures in postmenopausal women with thyroid disease. , 1993, Thyroid : official journal of the American Thyroid Association.

[23]  S P Robins,et al.  Automated analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography. , 1992, Analytical biochemistry.

[24]  T. Ohishi,et al.  Quantitative analyses of urinary pyridinoline and deoxypyridinoline excretion in patients with hyperthyroidism. , 1992, Endocrine research.

[25]  T. Diamond,et al.  A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. , 1991, The Journal of clinical endocrinology and metabolism.

[26]  J. Poser,et al.  Nuclear thyroid hormone receptors in cultured bone cells. , 1986, Metabolism: Clinical and Experimental.

[27]  S. Toh,et al.  Effect of hyperthyroidism and its treatment on bone mineral content. , 1985, Archives of internal medicine.

[28]  F. Melsen,et al.  Morphometric and dynamic studies of bone changes in hyperthyroidism. , 1977, Acta pathologica et microbiologica Scandinavica. Section A, Pathology.

[29]  S. Fraser,et al.  Osteoporosis and fractures following thyrotoxicosis. , 1971, Lancet.